Shares of Adamis Pharmaceuticals Corp. (ADMP) were down more than 34% in extended trading on Friday after the company’s New Drug Application for Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe product for the emergency treatment of acute anaphylaxis was sent back to the drawing board by the FDA. Anaphylaxis is a potentially life-threatening allergic reaction.